Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

303 results about "Anaphylaxis treatment" patented technology

The primary treatment of anaphylaxis is epinephrine injection into a muscle, intravenous fluids, and positioning the person flat. Additional doses of epinephrine may be required. Other measures, such as antihistamines and steroids, are complementary.

Protecting and fixing device for wound

The invention discloses a protecting and fixing device for wound, comprising at least one protecting and fixing layer with openings, wherein the protecting and fixing layer with openings is longitudinally provided with an opening for communicating the upper end face and the lower end face; the opening can enclose the wound therein so as to make the protecting and fixing layer with openings limit the wound tension and increase the mobile corrugation of the wounded skin. The invention can protect and fix the operation wound, the trauma wound or the catheter infusion wound into an opening which can limit the tension increase of the wound and the mobile corrugation of the surface skin of the wound and can prevent the wound from being torn and cracked and also avoid the damage for the wound due to the mobile corrugation and the surgical dressing of the wounded skin as well as the relative displacement frictions of the infusion catheter. Therefore, the invention fills the blank of current technology, which can enable the covered dressings to penetratively contact the secretion so as to absorb the exudate of the wound. Besides, the invention can prevent the foreign material contact anaphylaxis due to the wound contacting by compressing the dressing and the direct bonding of the catheter infusion wound and can prevent the re-injury of the wound caused by the synechia between the dressing and the wound secretion.
Owner:唐二虎 +2

Duplex dentin hypersensitivity resistant composition and application thereof

The invention discloses a duplex dentin hypersensitivity resistant composition and an application of the composition. The active ingredients of the duplex dentin hypersensitivity resistant composition include a potassium salt and titanium containing bioactive glass, wherein the weight percentage of the potassium salt in the composition is 0.3-12%, and the weight percentage of the titanium containing bioactive glass in the composition is 0.5-15%. The duplex dentin hypersensitivity resistant composition disclosed by the invention can be used for preventing and treating (eliminating or relieving) dentin hypersensitivity; on one side, the potassium salt releases potassium ions to rapidly relieve pain (by reducing the excitability of a dental pulp nerve), on the other side, the bioactive glass can be used for supplementing minerals for a tooth structure to form stable carbonated hydroxyapatite so as to deeply close a dentinal tubule (by improving the permeability of the dentinal tubule); treatment effect is greatly improved, and aching feeling and anaphylaxis can be radically eliminated to achieve the purposes of treating both symptoms and root causes; in addition, as the bioactive glass comprises titanium, the phosphorite layer formed on the surface of a tooth is firmer and more wear-resistant, and the tooth can better resist daily stimulation.
Owner:SAIKE SAISI BIOTECH CO LTD

Substituted heterocyclic compounds and methods of use

The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC

Substituted heterocyclic compounds and methods of use

The present invention relates to compounds having the general formula
or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products